Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering

Biohaven Ltd.

2022-Q3 EPS reported -$9.38

Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).
Cash at Sept 30: $50.7M; post-spin-off and $301.9M public offering, pro-forma cash ~$541M with no debt.
Spin-off from Pfizer completed Oct 3, 2022; BHVN began trading independently with $257.8M cash.
Closed public offering of 28.75M shares at $10.50/share, gross proceeds $301.9M (net $282.8M).
Pipeline milestones: BHV-7000 Phase 1 complete H1 2023; troriluzole Phase 3 OCD enrollment in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biohaven Ltd. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the third quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-22-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.